Results 131 to 140 of about 191,272 (307)

Haematopoietic stem cell transplantation outcomes for teenage and young adult patients with acute leukaemia: A British Society of Blood and Marrow Transplantation and Cellular Therapy registry study

British Journal of Haematology, EarlyView.
Summary Teenage and young adult (TYA) patients undergoing allogeneic stem cell transplant have distinct psychosocial needs, yet they are poorly represented in research and their outcomes are not well understood. This study uses prospectively collected data from the British Society of Blood and Marrow Transplantation and Cellular Therapy (BSBMTCT ...
Graham McIlroy, Ben Carpenter, Rachael Hough, Beki James, Caroline Besley, Emma Nicholson, Persis Amrolia, Oana Mirci‐Danicar, Caroline L. Furness, Brenda Gibson, Victoria Potter, Rachel Pearce, Julia Lee, Clementina Abamba, Anna Castleton, Ram Malladi   +15 more
wiley   +1 more source

Serum free light chain concentration and ratio‐based criterion for myeloma‐defining event, in its current version, is untenable

British Journal of Haematology, EarlyView.
Summary Clinical decision‐making based on myeloma‐defining event criteria using thresholds for involved serum free light chain level of 10 mg/dL and ratio of involved to uninvolved light chain of >100 is a poor indicator for the risk of progression to multiple myeloma.
Gurmukh Singh
wiley   +1 more source

MRD‐negative conversion with daratumumab monotherapy in newly diagnosed multiple myeloma patients in ≥VGPR/MRD‐positive after first‐line therapy: Final analysis of the open‐label, single‐arm multicentric phase 2 trial DART4MM

British Journal of Haematology, EarlyView.
In newly diagnosed multiple myeloma patients in ≥Very Good Partial Remission (VGPR) after a first‐line therapy daratumumab as consolidation/maintenance improved long‐term minimal residual disease negativity. Summary Daratumumab is approved for front‐line and relapsed myeloma therapy.
Alessandro Gozzetti, Paola Pacelli, Federico Caroni, Donatella Raspadori, Elena Bestoso, Elisabetta Antonioli, Gabriele Buda, Sara Ciofini, Adele Santoni, Luca Puccetti, Francesca Bacchiarri, Ludovica Pengue, Dania Tocci, Irene Attucci, Maria Livia del Giudice, Miriana Ruggieri, Alessandra Lombardo, Anna Marina Liberati, Veronica Candi, Vincenzo Sammartano, Alessandra Cartocci, Anna Sicuranza, Sara Galimberti, Alessandro Maria Vannucchi, Monica Bocchia   +24 more
wiley   +1 more source

Treosulfan–fludarabine conditioning in infants with severe combined immunodeficiencies: Extended study of the UK paediatric treosulfan study

British Journal of Haematology, EarlyView.
Summary Allogeneic haematopoietic stem cell transplantation (HSCT) is a curative therapy for severe combined immunodeficiency (SCID). Conditioning improves donor engraftment and freedom from immunoglobulin replacement (IgR) but increases the risks of acute and late toxicity. Treosulfan, a reduced toxicity alkylating agent, has emerged as an alternative
Su Han Lum, Sinéad Greener, Irum Latif Memon, Persis Amrolia, Zohreh Nademi, Robert Chiesa, Juliana Silva, Helen Young, Stephen Owens, Eleri Williams, Khuen Foong Ng, Terry Flood, Andrew R Gennery, Sophie Hambleton, Kanchan Rao, Mary Slatter   +15 more
wiley   +1 more source

Benefit of selinexor dose reduction on outcomes with selinexor, bortezomib and dexamethasone in patients with lenalidomide‐refractory multiple myeloma: Subgroup analysis of the BOSTON trial

British Journal of Haematology, EarlyView.
A subgroup analysis of efficacy, safety and QOL in patients who received selinexor in combination with bortezomib and dexamethasone (SVd) with and without selinexor dose reduction and who had lenalidomide‐refractory disease in the phase 3 BOSTON trial showed improvements in efficacy, quality of life (QOL) and safety outcomes with selinexor dose ...
Sosana Delimpasi, Ivan Špička, Jason P. Butler, Don A. Stevens, Mercedes Gironella Mesa, Ceri Bygrave, Giovanni Marino Merlo, Charles la Porte, Meletios A. Dimopoulos   +8 more
wiley   +1 more source

Functional high‐risk phenotype predicts poor survival in multiple myeloma independent of front‐line treatment: A secondary analysis of CIBMTR data

British Journal of Haematology, EarlyView.
Summary Functional high‐risk (FHR) multiple myeloma (FHRMM) is often defined as progression within 12–24 months of front‐line autologous hematopoietic stem cell transplantation (AHSCT). For patients with early progression after suboptimal front‐line therapies, it is challenging to assign the disease progression to a true FHR phenotype versus less ...
Utkarsh Goel, Catalin Dragomirescu, Saurabh Zanwar, Rafaella Cassano Cassano, Kara I. Cicero, Andrew J. Cowan, Rahul Banerjee, Faiz Anwer, Jack Khouri, Danai Dima   +9 more
wiley   +1 more source

Improved survival with fludarabine‐based therapies in mixed phenotype acute leukaemia: A population‐based study using the WHO 2022 classification

British Journal of Haematology, EarlyView.
Summary Mixed phenotype acute leukaemia (MPAL) is a rare subtype of acute leukaemia possessing significant therapeutic challenges, as no standardized, evidence‐based treatment regimen has been defined. In this nationwide study, we aimed to assess the effect of an acute lymphoid leukaemia (ALL)‐like regimen; an acute myeloid leukaemia (AML)‐like regimen;
Lisa‐Maj Christensen, Mikkel Runason Simonsen, Jonas Faartoft Jensen, Daniel Tuyet Kristensen, Karen Dybkær, Kirsten Grønbæk, Tarec Christoffer El‐Galaly, Marianne Schmidt Ettrup, Hans Beier Ommen, Anne Louise Tølbøll Sørensen, Dennis Lund Hansen, Marianne Tang Severinsen   +11 more
wiley   +1 more source

High frequency of CD95+/CD45RA− regulatory T cells defines an immunosuppressive profile associated with MDS progression

British Journal of Haematology, EarlyView.
Summary Dynamic interactions between mutated haematopoietic cells and immune cells are key drivers of myelodysplastic neoplasms (MDS) initiation and progression. Regulatory T cells (Tregs) are central mediators of immunosuppression in MDS. We thus aimed to characterize Treg subpopulations in the bone marrow (BM) of MDS patients and to explore their ...
Romain Vazquez, Nicolas Deredec, Ismael Boussaid, Pierre Boncoeur, Camille Knosp, Amandine Houvert, Loria Zalmai, Chloe Friedrich, Carole Almire, Charles Dussiau, Lise Willems, Rudy Birsen, Justine Decroocq, Didier Bouscary, Olivier Kosmider, Shahram Kordasti, Michaela Fontenay, Yannick Simoni, Nicolas Chapuis   +18 more
wiley   +1 more source

A Rare Cytogenetic Presentation of Acute Myeloid Leukemia (AML-M2)

Acta Medica Iranica, 2012
Acute myeloid leukemia (AML) with t(8;21)(q22;q22) generating the AML1/ETO fusion gene on 8q22 is a distinct type of AML t(8;21) category (WHO)/AML-M2 (FAB), generally associated with a favourable prognosis.
Prasanna Kumari, Bidadi LingappaKavitha, Chintaparthi Obula Reddy, Maiana Mangalagowri, Danem Satienariana Madhumathi, Madaiah Mahadeva Prasad, Hanumanthappa Vijay Raghavendra, Chennagiri Shinivasa Murthy Premalata, Kuntejowdahalli Channaviriappa Lakshmaiah, Seyed Hashem Mir Mazloumi   +9 more
doaj  

Day‐30 IL1RL1, CXCL9 and REG3α are prognostic for survival after mismatched unrelated donor transplantation

British Journal of Haematology, EarlyView.
Summary While plasma‐derived proteins have emerged as potential biomarkers for prognosis after haematopoietic stem cell transplantation (HSCT), there are insufficient data assessing if established proteins interleukin 1 receptor‐like 1 (IL1RL1), chemokine ligand 9 (CXCL9) and regenerating islet‐derived 3‐α (REG3α) retain their utility in the mismatched
Trent Wang, Anna C. Ferreira, Nasheed M. Hossain, Denggang Fu, Elizabeth G. Hill, Antonio M. Jimenez Jimenez, Cara Benjamin, Krishna V. Komanduri, Sophie Paczesny   +8 more
wiley   +1 more source